Last Price
22.93
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
71 Million
Shares Outstanding
3 Million
Avg Volume
27,036
Avg Price (50 Days)
20.19
Avg Price (200 Days)
8.35
PE Ratio
-5.73
EPS
-4.00
Earnings Announcement
07-Aug-2024
Previous Close
22.80
Open
22.93
Day's Range
22.75 - 22.94
Year Range
3.145 - 22.94
Trading Volume
50,899
1 Day Change
0.00%
5 Day Change
0.00%
1 Month Change
0.58%
3 Month Change
192.85%
6 Month Change
578.40%
Ytd Change
430.79%
1 Year Change
562.72%
3 Year Change
-79.65%
5 Year Change
-80.89%
10 Year Change
-80.89%
Max Change
-80.89%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.